Let's take a look at the risks associated with structured investment products, both for investors who use them and for the banks that create and hedge them. Starting with investors, structured products introduce a range of risks beyond those seen in standard investments. One of the biggest concerns is liquidity. Unlike exchange traded securities, many structured products are not actively traded in secondary markets. This means that selling before maturity is often only possible through the issuing bank, and the exit price may be significantly lower than the initial investment due to wide-bid offer spreads, hedging costs and markups. Structured products are typically designed as buy and hold investments, making them unsuitable for short term trading. Another key issue is complexity.

Structured products often involve intricate payout structures, embedded derivatives, and terms that require careful interpretation. Investors may struggle to fully understand the risks, particularly the sensitivity to factors like volatility, correlation, and interest rate movements. Misinterpreting how these variables impact returns can lead to unexpected losses. The potential loss of capital is another major factor. While some structured products offer principle protection, many do not. Products linked to market movements such as reverse convertibles or buffered notes, can result in investors receiving significantly less than their initial investment if market conditions move against them. In extreme cases, certain structured products can lead to a total loss of capital. Transparency is also a challenge. Unlike standard bonds or stocks, pricing structured products is not straightforward. There is typically limited transparency on the market value of a structured product after issuance, making it difficult for investors to assess their unrealized gains or losses. Furthermore, banks do not disclose how they price each component of the structure, nor do they typically reveal their markups, which can vary significantly. Another concern is credit risk on the issuer. If a structured note is issued by a bank or another financial institution, investors are exposed to the credit worthiness of that issuer. If the bank defaults, investors could lose their entire investment, even if the underlying assets perform well. For structured products that rely on derivatives rather than debt issuance, investors face counterparty risk, the risk that the issuing bank or another institution fails to meet its derivative obligations. Finally, opportunity cost is often overlooked. Many structured products trade off the potential for upside with downside protection or enhanced yield, which may not always be favorable. If markets move in a favorable direction, investors may find that they would've been better off holding a simpler investment like a direct equity position or a fixed income instrument. Now, let's turn to the risks faced by banks that structure issue and hedge these products. The most immediate risk is market risk, which includes sensitivities to all the Greeks, such as delta price movements, gamma convexity effects, vega volatility risk, theta time decay, and rho interest rate sensitivity. Certain structures such as barrier and digital options can have non-linear payouts. Where small market moves trigger disproportionately large changes in returns, making risk management more complex. Correlation risk is another major challenge. If a product's performance is linked to the relationship between multiple assets, it can be difficult or impossible to hedge effectively. Banks also face model risk. Structured products rely on sophisticated quantitative models to price embedded options and derivatives. If a model is flawed, it can lead to systematic mispricing, exposing the bank to unexpected losses. To mitigate this, banks typically have independent model validation teams that review and approve all pricing models before they are used in live trading. Another consideration is the in-house expertise required to run a structured products business. These products require knowledge across multiple areas, not just in the front office, but also in middle and back office functions, quant teams, risk management, compliance, and technology. Without sufficient expertise across these functions, banks risk operational inefficiencies, pricing errors, and regulatory scrutiny. Valuation challenges also play a role. Many structured products, particularly those with exotic derivatives, do not have clear market prices. Some components such as correlation risk or moving barriers may not have liquid hedging instruments making it difficult to determine a fair market value. This lack of independent pricing transparency can be problematic for both banks and their clients. Lastly, mis-selling to Clients is a significant reputational and regulatory risk. Given the complexity of structured products, banks must provide adequate risk disclosure to clients ensuring they have the necessary information to make informed decisions. There have been cases where investors, particularly retail or unsophisticated clients, did not realize the full extent of their downside exposure. If products are not sold appropriately, banks face potential fines, legal action, and damage to their reputation. Regulators in many jurisdictions have tightened oversight to ensure structured products are marketed responsibly, particularly to retail investors. Mis-selling can also strain client relationships and lead to lost business opportunities in the future.